Hypoxia as a barrier to immunotherapy in pancreatic adenocarcinoma

Overview of attention for article published in Clinical and Translational Medicine, April 2019

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 3 X users

Citations

dimensions_citation: 163 Dimensions

Readers on

mendeley: 139 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 2,795 followers.

@DrMSodergren @imperialcollege @DJPinato Tumour hypoxia is emerging as a barrier to immunotherapy in many aggressive solid tumours. Hypoxia biomarker-stratified trials combining hypoxia-activated prodrugs and immunotherapy are required. https://t.co/e91FLT

24 Oct 2019

Reply Repost Favourite

Hypoxia as a barrier to immunotherapy in pancreatic adenocarcinoma. https://t.co/jdBOI9Dv4R

03 Apr 2019

Reply Repost Favourite

Hypoxia as a barrier to immunotherapy in pancreatic adenocarcinoma. https://t.co/LJtvPfN9r4

02 Apr 2019

Reply Repost Favourite